Trial reportBMJ (Clinical research ed.)2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
Trial report in BMJ (Clinical research ed.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04453826 (A Multicenter Randomized Clinical Phase 3 Trial of Induction Chemotherapy Plus Concurrent Chemo-radiotherapy With or Without Camrelizumab for High Risk Nasopharyngeal Carcinoma), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Randomized Clinical Phase 3 Trial of Induction Chemotherapy Plus Concurrent Chemo-radiotherapy With or Without Camrelizumab for High Risk Nasopharyngeal Carcinoma
Who cites it
3 citing papers in PubMed.
- The current role of immunotherapy in treating nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2026Review
- Nasopharyngeal carcinoma: epidemiology, risk factors, signaling pathways, clinical features, diagnosis, and management.Molecular biomedicine · 2026Review
- Integrated bioinformatics and experimental validation identifies CLIC6 as a novel tumor suppressor regulating NF-κB signaling and immune microenvironment in nasopharyngeal carcinoma.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma.
designMulticentre, randomised, open label, phase 3 trial.
settingSeven hospitals in China between 18 August 2020 and 21 June 2022.
participantsAdults aged 18-70 years with newly diagnosed high risk nasopharyngeal carcinoma after three cycles of induction chemotherapy with gemcitabine and cisplatin (stage 4a, stage 2-3 with stable or progressive disease, or detectable Epstein-Barr virus DNA).
interventionsPatients were randomly assigned (1:1) to receive combination chemoradiotherapy based on cisplatin (standard treatment group) or standard treatment with 19 cycles of intravenous camrelizumab (200 mg) once every three weeks (radiotherapy plus two concurrent cycles and 17 adjuvant cycles; camrelizumab group).
main outcome measuresThe primary endpoint in the intention-to-treat group was progression-free survival, defined as the time from randomisation to disease recurrence (locoregional or distant) or death from any cause. Secondary endpoints included safety and overall survival.
results390 patients were enrolled and randomly assigned to the camrelizumab group (n=194) or the standard treatment group (n=196). At median follow-up of 39.9 months (interquartile range 36.8-43.4 months), progression-free survival was higher in the camrelizumab group than the standard treatment group (36 months: 83.4%, 95% confidence interval 78.3% to 88.8%
conclusionThe addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy.
trial registrationClinicalTrials.gov NCT04453826.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.